Insight Molecular Diagnostics Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Insight Molecular Diagnostics Inc. (IMDX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $536.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-11.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-03-11
- Insight Molecular Diagnostics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Insight Molecular Diagnostics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $0.00.
- Insight Molecular Diagnostics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was $0.00.
- Insight Molecular Diagnostics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $536.00K.
- Insight Molecular Diagnostics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $536.00K, a 81.30% decline from fiscal 2019.
- Insight Molecular Diagnostics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $2.87M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 derived: sum of 3 quarters · filed 2022-03-11 | $536.00K 10-K · filed 2022-03-11 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $536.00K 10-Q · filed 2021-11-09 | $3.00M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $536.00K 10-Q · filed 2021-08-11 | $3.00M derived: sum of 3 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $536.00K 10-Q · filed 2021-05-17 | $3.39M 10-Q · filed 2020-05-12 | $3.00M derived: sum of 2 quarters · filed 2021-05-17 | ||
| 2019-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $2.87M 10-K · filed 2020-03-26 | |||
| 2019-09-30 | $397.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |